LINAGLIPTIN - Generic Drug Details

What are the generic sources for linagliptin and what is the scope of patent protection?

Linagliptin is the generic ingredient in five branded drugs marketed by Aurobindo Pharma Ltd, Dr Reddys, Invagen Pharms, MSN, Mylan, Sunshine, Zydus Pharms, and Boehringer Ingelheim, and is included in fourteen NDAs. There are sixteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Linagliptin has three hundred and eighty-one patent family members in forty-one countries.

There are nineteen drug master file entries for linagliptin. Three suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for LINAGLIPTIN

International Patents:	381
US Patents:	16
Tradenames:	5
Applicants:	8
NDAs:	14
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	152
Patent Applications:	5,038
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LINAGLIPTIN
What excipients (inactive ingredients) are in LINAGLIPTIN?	LINAGLIPTIN excipients list
DailyMed Link:	LINAGLIPTIN at DailyMed

Recent Clinical Trials for LINAGLIPTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AJU Pharm Co., Ltd.	PHASE1
Huazhong University of Science and Technology	PHASE4
The First Affiliated Hospital of Nanchang University	PHASE4

See all LINAGLIPTIN clinical trials

Generic filers with tentative approvals for LINAGLIPTIN

Applicant	Application No.	Strength	Dosage Form
		2.5MG;1GM	TABLET;ORAL
		2.5MG;850MG	TABLET;ORAL
		2.5MG;500MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LINAGLIPTIN

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Medical Subject Heading (MeSH) Categories for LINAGLIPTIN

Dipeptidyl-Peptidase IV Inhibitors

Hypoglycemic Agents

Incretins

Anatomical Therapeutic Chemical (ATC) Classes for LINAGLIPTIN

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for LINAGLIPTIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRADJENTA	Tablets	linagliptin	5 mg	201280	11	2015-05-04

US Patents and Regulatory Information for LINAGLIPTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	LINAGLIPTIN	linagliptin	TABLET;ORAL	208448-001	Mar 30, 2023	AB	RX	No	No
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	8,883,805*PED				Y
Dr Reddys	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE	linagliptin; metformin hydrochloride	TABLET;ORAL	208427-003	Nov 3, 2025	AB	RX	No	No

Expired US Patents for LINAGLIPTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	7,459,428
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	8,178,541
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	6,303,661

EU/EMA Drug Approvals for LINAGLIPTIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Trajenta	linagliptin	EMEA/H/C/002110Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.	Authorised	no	no	no	2011-08-23

International Patents for LINAGLIPTIN

Country	Patent Number	Title	Estimated Expiration
Argentina	072920
Australia	2009279085
Brazil	PI0916997

Supplementary Protection Certificates for LINAGLIPTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	PA2012022	Lithuania		PRODUCT NAME: LINAGLIPTINUM + METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/12/780/001 - EU/1/12/780/034 20120720
1532149	C01532149/01	Switzerland		PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012
2187879	LUC00017	Luxembourg		PRODUCT NAME: GLYXAMBI- EMPAGLIFLOZINE/LINAGLIPTINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1146 20161115

Linagliptin market dynamics and financial trajectory: sales drivers, pricing pressure, generic/biosimilar risk, and expected revenue path

Last updated: June 21, 2026

Linagliptin (DPP-4 inhibitor; brands include Tradjenta) has shifted from growth to a mature, competitive market characterized by (1) strong class-based demand for type 2 diabetes, (2) ongoing price pressure as payer formularies optimize for cost, and (3) gradual share erosion as low-cost competitors expand. Financial trajectory since peak has been shaped more by pricing and competitive mix than by new mechanism differentiation.

---

How big is the linagliptin market and what sales trajectory has the drug shown?

Featured answer: Linagliptin is a mature, branded diabetes product with sales supported by broad T2D label utility and combination use, while growth has been constrained by generic entry risk and payer cost controls typical for DPP-4 inhibitors.

What are the commercial drivers of linagliptin uptake?

Linagliptin demand has historically benefited from:

• Once-daily oral dosing that fits chronic T2D adherence patterns.
• Combination therapy compatibility (with metformin and other agents) supporting formulary positioning.
• Renal considerations (clinical profile supports use in patients with chronic kidney disease, a key payer and clinician decision factor in T2D management).

What structurally limits revenue growth?

• Class competition: DPP-4 inhibitors are therapeutically substitutable, so differentiation is payer-visible only when clinical or safety advantages translate into formulary leverage.
• Formulary steering: PBMs increasingly favor lower net price per A1c-lowering equivalent.
• Genericization timeline dynamics: Even when patent estates delay generic entry, price pressure begins through contracting before full loss of exclusivity.

---

Who sells linagliptin and how do the key business units influence financial performance?

Featured answer: Linagliptin’s branded commercial performance is tied primarily to the product’s owner and license partners’ diabetes franchise operations, with quarterly revenue exposed to US and ex-US net price and volume.

What company-level levers determine linagliptin net sales?

• Territory mix (US vs EU vs other geographies) drives realized price because rebate structures differ.
• Contracting velocity: Rapid payer switches to lower-cost alternatives can compress revenue even before hard generic launch.
• Trade-down: Patients shift to cheaper DPP-4 options when payer coverage changes.

What do segment trends indicate for the drug?

For branded diabetes portfolios, revenue tends to track:

• New prescription growth early on, then
• Sustained maintenance volume after maturity, and then
• Decline in net price and share when generics or parallel-in-market cost pressures accelerate.

---

What patents protect linagliptin and how do they shape market exclusivity?

Featured answer: Linagliptin’s exclusivity depends on a layered patent stack covering the active ingredient, specific formulations/dosage forms, combination products, and manufacturing processes, with legal challenges determining timing of generic entry.

How does patent estate structure affect revenue timing?

• Active ingredient patents set the outer boundary for full generic substitution.
• Formulation and method-of-use patents can delay certain generics or force “carve-outs” for specific dosage forms or claims.
• Orange Book listing granularity determines how many Paragraph IV opportunities exist and whether settlements defer entry.

What typical “bottleneck” patents matter for DPP-4s like linagliptin?

• Table-ready oral tablet formulation patents and specific dosage strength claims.
• Manufacturing method patents tied to polymorph control or granulation parameters.
• Combination patents for co-formulated products.

(Note: Patent numbers, jurisdictions, and Orange Book entries are required for an exact estate map. This response is limited to market dynamics and financial trajectory.)

---

When does linagliptin lose exclusivity, and what does that mean for revenue risk?

Featured answer: Revenue risk increases in phases: (1) pre-launch payer contracting, (2) first generic entry, and (3) follow-on generics that deepen price erosion.

Exclusivity phases that typically drive financial step-down

1. Pre-expiry discounting: PBMs rebid coverage based on expected generic pricing.
2. First generic launch: Net price falls quickly because competing wholesalers and PBMs push substitution.
3. Multi-generic normalization: A second wave of generics compresses margins further and accelerates share losses.

What financial behavior to expect around generic entry

• Sharp margin compression even if total volume holds temporarily.
• Ongoing decline after channel inventory normalizes and formulary dominance shifts.
• Increased spend on contracting, copay programs, and retention to defend share.

---

What generic entry risks exist for linagliptin in the US, and how do they affect near-term forecasts?

Featured answer: Generic entry risk for linagliptin is the dominant near-term determinant of branded revenue after maturity, with financial impact primarily driven by net price and channel substitution rather than total market size.

What drives the magnitude of price erosion?

• Number of authorized generics or AB-rated filers (market structure).
• PBM preferred-tier mechanics (how quickly the branded product is relegated).
• Settlements and launch design (timing and scope of Paragraph IV resolutions).
• Formulation equivalency (whether switching is frictionless).

How does the risk translate into revenue mechanics?

• First measurable effect: net sales per unit decline.
• Later effect: volume share deterioration.
• Persistent effect: rebate escalation to retain contracts.

---

What patent litigation and Paragraph IV challenges can influence linagliptin market timing?

Featured answer: Patent disputes and Paragraph IV challenges determine whether generic entry occurs at the earliest feasible time, later via design-around, or is deferred through settlement.

How do litigation outcomes usually map to financial trajectory?

• Win for brand: maintains branded economics longer, delaying net price compression.
• Loss for brand or early resolution: triggers immediate or staged generic entry.
• Settlement: often creates a structured launch schedule that can still drive revenue decline but may soften timing versus worst-case.

(No specific case captions, dates, or settlement terms are included because the request requires market dynamics rather than legal record mapping. Exact litigation details require docket-level inputs.)

---

What is the Orange Book status of linagliptin products and what does it imply for generics?

Featured answer: Orange Book listings indicate which patents could be used to trigger Paragraph IV challenges and which types of exclusivity may persist for particular strengths or dosage forms. The more “listed” patents, the greater the legal and timing complexity for generic entry.

How do Orange Book listings affect filing strategy?

• Multiple listed patents create more potential for partial entry or launch segmentation.
• Filing around specific claims can limit infringement risk while still enabling a product launch.

---

How strong is the patent estate for linagliptin compared with other DPP-4 inhibitors?

Featured answer: The DPP-4 category typically features aging, layered patent estates that gradually narrow as generics approach; relative strength depends on jurisdiction-specific filing depth and the number of “still-listed” patents near expiration.

What competitive categories matter for linagliptin’s commercial outcome?

• Other DPP-4 inhibitors competing for similar formularies (e.g., those with established generic presence).
• Therapeutic substitutes outside DPP-4 class (GLP-1 receptor agonists, SGLT2 inhibitors) that increasingly capture prescriber and payer mindshare for cardiovascular and renal outcomes.

---

How does linagliptin compare with competitors on market share and payer positioning?

Featured answer: Linagliptin competes primarily as a DPP-4 option on efficacy equivalence and patient suitability, with payer incentives increasingly shaped by net pricing and class switching behavior.

What are the market-facing differences that impact sales?

• Net price competitiveness after genericization across the class.
• Formulary tier placement and prior authorization requirements.
• Clinical preference segments (renal disease management, tolerability concerns, adherence needs).

What trade patterns typically occur?

• When low-cost DPP-4s are available, branded linagliptin share erodes even in patient segments where physicians consider it a good fit.
• As GLP-1 and SGLT2 uptake grows, DPP-4 prescriptions can decline in the marginal patient population.

---

What formulations and combination products drive linagliptin revenue stability?

Featured answer: Revenue stability usually comes from tablet strengths and combination regimens that match payer formularies and prescribing routines.

What product-line behavior matters financially?

• Strength-specific demand affects unit mix and realized price.
• Combination use can defend revenue by embedding linagliptin into multi-drug pathways that are harder to switch wholesale.

---

Where is linagliptin most exposed to ex-US pricing pressure and government tendering?

Featured answer: Ex-US revenues generally face sharper pricing pressure where reimbursement systems use reference pricing, tender auctions, or mandatory cost-containment policies.

What commercial mechanisms drive revenue compression outside the US?

• Reference pricing caps reimbursement, pushing net price down.
• Tender dynamics can rapidly install the lowest-cost supplier.
• Parallel trade can distort channel economics and discounting structure.

---

What regulatory pathways shape competitive timelines for linagliptin generics?

Featured answer: Generic competition is mainly driven by ANDA approvals (and Para IV challenges where relevant), while any biologic pathway is not applicable because linagliptin is a small molecule.

What are the key regulatory timing levers?

• FDA approval timing relative to litigation outcomes.
• Labeling and bioequivalence for substitution readiness.
• Launch readiness and supply determining whether approvals translate into immediate market capture.

---

What commercial outlook is implied for linagliptin revenue and profitability?

Featured answer: The financial trajectory should be expected to follow a mature-branded pattern: continued but limited volume growth, then sustained net price and margin compression as competition intensifies, with the steepest revenue decline typically occurring around major generic entry milestones.

Revenue exposure map (practical view for forecasting)

Revenue driver	Maturity-stage effect	Typical direction under competition
Unit volume	Stabilizes after initial growth	Downshift as formulary switching accelerates
Realized net price	Contracted heavily by PBMs and payers	Down sharply on generic entry
Rebates/discounts	Increase to defend tier placement	Rise, compressing gross-to-net
Product mix	Strength and combination composition	Shifts toward lower-priced equivalents
Territory mix	US tends to have slower tendering mechanics than some EU markets	Ex-US can erode faster via reference pricing

What matters most for financial modeling

• Assume net price step-down at launch events.
• Model share loss curve rather than a flat decline: substitution and tender policies determine how quickly share falls.
• Include channel inventory effects around discontinuation of branded supply or major replenishment cycles.

---

Key Takeaways

• Linagliptin is in the mature phase of a DPP-4 market where financial performance is dominated by net pricing and formulary tier placement rather than demand expansion.
• Patent and exclusivity dynamics shape the timing of generic substitution, which typically triggers the sharpest revenue step-down.
• Competitive pressure is multi-source: other DPP-4 inhibitors with generic presence, plus incremental substitution from GLP-1 and SGLT2 classes in appropriate patient segments.
• Ex-US pricing and reimbursement systems can accelerate margin erosion through reference pricing and tendering.
• Revenue forecasting should center on a staged scenario: pre-expiry contracting, first generic launch impact, then follow-on erosion.

---

FAQs

1. How quickly do DPP-4 inhibitors lose branded share after first generic launch?
   Share declines depend on PBM switching mechanics and tender/reference pricing in each territory, often after a short lag tied to reimbursement updates and inventory.

2. Does combination therapy with metformin or other agents reduce linagliptin revenue volatility?
   Combination products can slow share losses because switching requires multi-drug regimen changes, but net price still erodes under generic competition.

3. What payer factors most influence linagliptin net price decline?
   Contracting terms, rebate structures, preferred-tier placement, and prior authorization policies.

4. How do renal-patient segments affect linagliptin formulary placement?
   Clinician and payer acceptance in CKD patient subgroups can support baseline demand, but cost-based formularies can still steer substitution.

5. What are the biggest threats to linagliptin long-term revenue beyond generics?
   Uptake of SGLT2 inhibitors and GLP-1 receptor agonists in populations where payers prioritize demonstrated cardiovascular and renal outcome benefits.

---

References

(No sources were cited because the prompt requires market dynamics and financial trajectory without providing specific patent litigation records, Orange Book listings, FDA milestones, or financial statement figures.)